Literature DB >> 23489216

Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial.

B Lee Peterlin1, Gretchen E Tietjen, Barbara A Gower, Thomas N Ward, Stewart J Tepper, Linda W White, Paul D Dash, Edward R Hammond, Jennifer A Haythornthwaite.   

Abstract

OBJECTIVE: To assess ictal adiponectin (ADP) levels before and after acute abortive treatment in women episodic migraineurs.
METHODS: Peripheral blood specimens were collected from women episodic migraineurs before and after acute abortive treatment with sumatriptan/naproxen sodium vs placebo. Univariate and multivariate models were utilized to examine the relationship between serum total ADP (T-ADP), ADP oligomers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]-ADP), and ADP ratio levels and pain severity. Paired t-tests and random intercept longitudinal models were utilized to assess the mean changes in T-ADP, ADP oligomers, and ratios over time in treatment responders and nonresponders.
RESULTS: Twenty participants (11 responders, 9 nonresponders) have been studied to date. In all participants, increases in the HMW : LMW ADP ratio were associated with an increase in pain severity. For every 1 point increase in the HMW : LMW ratio, pain severity increased by 0.22 (Confidence Interval [CI]: 0.07, 0.37; P = .004). In contrast, for every 0.25 μg/mL increase in LMW-ADP, pain severity decreased by 0.20 (CI: -0.41, -0.002; P = .047). In treatment responders, T-ADP levels were reduced at 30 minutes (12.52 ± 3.4; P = .03), 60 minutes (12.32 ± 3.2; P = .017), and 120 minutes (12.65 ± 3.2; P = .016) after treatment as compared with onset (13.48 ± 3.8). Additionally, in responders, the HMW : LMW ratio level was greater at pain onset (3.70 ± 1.9 μg/mL) as compared with nonresponders (2.29 ± 0.71 μg/mL), P = .050. Responders also showed a decrease in the HMW : LMW ratio at 60 minutes (2.37 ± 1.1; P = .002) and 120 minutes (2.76 ± 1.4; P = .02) after treatment as compared with onset (3.70 ± 1.9). These changes in responders remained significant after adjusting for covariates, including measured body mass index (m-BMI). Although nonresponders showed no significant changes in unadjusted T-ADP or ADP oligomer or ratio levels, the HMW : LMW ratio was increased in nonresponders after adjustments (P = .025).
CONCLUSION: In this pilot study of women episodic migraineurs, the HMW : LMW ADP ratio level was associated with migraine severity and predictive of acute treatment response. ADP and the HMW : LMW ratio of ADP represent potential novel biomarkers and drug targets for episodic migraine.
© 2013 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23489216      PMCID: PMC3601586          DOI: 10.1111/head.12071

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  18 in total

1.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

2.  Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.

Authors:  Konstantinos Karmiris; Ioannis E Koutroubakis; Costas Xidakis; Maria Polychronaki; Theodora Voudouri; Elias A Kouroumalis
Journal:  Inflamm Bowel Dis       Date:  2006-02       Impact factor: 5.325

3.  Association between obesity and psychiatric disorders in the US adult population.

Authors:  Gregory E Simon; Michael Von Korff; Kathleen Saunders; Diana L Miglioretti; Paul K Crane; Gerald van Belle; Ronald C Kessler
Journal:  Arch Gen Psychiatry       Date:  2006-07

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Comorbidity of migraine and depression: investigating potential etiology and prognosis.

Authors:  N Breslau; R B Lipton; W F Stewart; L R Schultz; K M A Welch
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

Review 6.  Adiponectin receptor signalling in the brain.

Authors:  John Thundyil; Dale Pavlovski; Christopher G Sobey; Thiruma V Arumugam
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells.

Authors:  Joachim Spranger; Sulekha Verma; Isabel Göhring; Thomas Bobbert; Joseph Seifert; Amy L Sindler; Andreas Pfeiffer; Stanley M Hileman; Matthias Tschöp; William A Banks
Journal:  Diabetes       Date:  2006-01       Impact factor: 9.461

Review 8.  Adiponectin and adiponectin receptors.

Authors:  Takashi Kadowaki; Toshimasa Yamauchi
Journal:  Endocr Rev       Date:  2005-05       Impact factor: 19.871

9.  Plasma cytokine levels in migraineurs and controls.

Authors:  Francesco Perini; Giovanni D'Andrea; Elisabetta Galloni; Francesco Pignatelli; Giuseppe Billo; Sabrina Alba; Gennaro Bussone; Vito Toso
Journal:  Headache       Date:  2005 Jul-Aug       Impact factor: 5.887

10.  A six-item short-form survey for measuring headache impact: the HIT-6.

Authors:  M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

View more
  9 in total

1.  Ictal adipokines are associated with pain severity and treatment response in episodic migraine.

Authors:  Nu Cindy Chai; Bizu Gelaye; Gretchen E Tietjen; Paul D Dash; Barbara A Gower; Linda W White; Thomas N Ward; Ann I Scher; B Lee Peterlin
Journal:  Neurology       Date:  2015-03-06       Impact factor: 9.910

Review 2.  Adipokines and Migraine: A Systematic Review.

Authors:  B Lee Peterlin; Simona Sacco; Claudia Bernecker; Ann I Scher
Journal:  Headache       Date:  2016-03-25       Impact factor: 5.887

3.  Interictal, circulating sphingolipids in women with episodic migraine: A case-control study.

Authors:  B Lee Peterlin; Michelle M Mielke; Alex M Dickens; Subroto Chatterjee; Paul Dash; Guillermo Alexander; Rebeca V A Vieira; Veera Venkata Ratnam Bandaru; Joelle M Dorskind; Gretchen E Tietjen; Norman H Haughey
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

4.  Adiponectin and leptin levels in migraineurs in the Atherosclerosis Risk in Communities Study.

Authors:  Jennifer L Dearborn; Andrea L C Schneider; Rebecca F Gottesman; Tobias Kurth; James S Pankow; David J Couper; Kathryn M Rose; Michelle A Williams; B Lee Peterlin
Journal:  Neurology       Date:  2014-11-05       Impact factor: 9.910

5.  Migraine and obesity: moving beyond BMI.

Authors:  Ana Recober; B Lee Peterlin
Journal:  Future Neurol       Date:  2014-01-01

Review 6.  Obesity and headache: Part II--potential mechanism and treatment considerations.

Authors:  Nu Cindy Chai; Dale S Bond; Abhay Moghekar; Ann I Scher; B Lee Peterlin
Journal:  Headache       Date:  2014-02-11       Impact factor: 5.887

Review 7.  Adiponectin and migraine: systematic review of clinical evidence.

Authors:  Giuseppe Lippi; Tiziana Meschi; Camilla Mattiuzzi; Loris Borghi; Giovanni Targher
Journal:  Neurol Sci       Date:  2014-03-20       Impact factor: 3.307

8.  Assessment of Alteration of Serum Adiponectin Levels in Migraineurs: An Interventional Case Control Study.

Authors:  Siddarth S Joshi; S C Nemichandra; S Harsha; Akila Prashant; Shasthara Paneyala; Roshan Iqbal; K Vimala Christina Colaco
Journal:  Ann Neurosci       Date:  2021-02-26

9.  Comparison of Peripheral Biomarkers and Reduction of Stress Response in Patients With Major Depressive Disorders vs. Panic Disorder.

Authors:  Mi Jin Park; Eun Hye Jang; Ah Young Kim; Hyewon Kim; Hyun Soo Kim; Sangwon Byun; Han Young Yu; Hong Jin Jeon
Journal:  Front Psychiatry       Date:  2022-03-31       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.